Epigenetic Reprogramming to Target GBM Signaling in CARM1-Deficient Tumors
Official title: Exploiting Epigenetic Reprogramming of NGFR/NTRK Signaling in CARM1-Deficient Glioblastoma
Funded at Albert Einstein College of Medicine · NIH-11436847 · Data updated 2026-11-12
Aimed at adults with glioblastoma, this grant explores how epigenetic changes affect cancer cell signaling and whether targeting these pathways could make tumors more treatable.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $431,970 |
| NIH project number | 1R21CA316284-01 |
| Project ID | NIH-11436847 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with glioblastoma or related glioma stem-like cell–driven tumors who could participate in future translational studies or trials.
✕Less likely to help
Early-stage research may not yet translate to direct patient benefits in the near term.
What this research studies
Glioblastoma is a deadly brain cancer driven in part by glioma stem-like cells. The project tests how losing the epigenetic regulator CARM1 changes a cell’s NGFR/NTRK signaling and makes tumors more sensitive to a brain-penetrant inhibitor. Researchers will use gene editing, protein analyses, and chromatin studies to map the mechanism, then test drug responses in mouse models with human tumor cells. The work could reveal a new way to exploit tumor biology for therapy.
Why it matters
Potential benefit: If successful, the research could identify a new vulnerability in glioblastoma that can be targeted with existing drugs, potentially improving outcomes for patients.
How similar studies have gone: Preliminary data in the project suggest a mechanistic link between epigenetic changes and drug sensitivity, with some prior work showing promise in related signaling pathways.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Sidoli, Simone — Albert Einstein College of Medicine
- Study coordinator: Sidoli, Simone
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.